Precision biosciences stock.

The stock option was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision. The stock option …

Precision biosciences stock. Things To Know About Precision biosciences stock.

Precision BioSciences to Report Third Quarter Results on November 7, 2023. DURHAM, N.C., November 01, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone payments ...DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in …Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...

Insiders have purchased a total of 107,498 DTIL shares in the last 24 months for a total of $168,870.74 bought. Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), and Michael ...Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...

20 thg 11, 2020 ... Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® ...Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Nov 17, 2023 · In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ... Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.

DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target is $3.00. Patrick Trucchio has given ...

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences (NASDAQ: DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a new hire under the Nasdaq Listing Rule 5635(c)(4). The inducement, part of their Inducement Award Plan, allows the employee …Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS ®- based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update. In addition, following the platform-wide …Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee …Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real …

Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is ...Jun 21, 2022 · Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ... Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and ...DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …Precision BioSciences, Inc. (DTIL) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 0.3650 +0.0099 (+2.79%) At close: 04:00PM EST. 0.3798 +0.01 (+4.05%) After hours: 06 ... In June 2022, Precision announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, ... Precision Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts)Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...

Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...Precision BioSciences (Nasdaq:DTIL) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Precision …Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... Precision BioSciences' CEO is Michael Amoroso, appointed in Oct 2021, has a tenure of 2.08 years. total yearly compensation is $4.37M, comprised of 13.8% salary and 86.2% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $81.33K. The average tenure of the management team and the board of …On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.Nov 29, 2023 · The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. Read Next: Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications. Price Action: DTIL stock is up 5.54% at $13.33 during the market session on the last check Thursday. SHARE ...13 hours ago · Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ... From Luke: Backing out its $160 million cash balance, Precision is valued at merely $130 million — a cheap valuation for a promising gene-editing company with proprietary tech and a big pharma ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See the top stocks recommended by analysts >> DTIL market cap is currently $101 ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.. About Precision BioSciences, Inc. …

Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.46 per share a year ago.Aug 15, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. DURHAM, N.C., March 09, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...Company profile page for Precision Biologics Inc including stock price, company news, press releases, executives, board members, and contact informationPrecision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee …Avidity Biosciences ( RNA) stock is jumping over 15% in early trading after announcing that its alliance with Bristol-Myers Squibb ( BMY) had been greatly …

DTIL (Precision BioSciences Inc.): A Small Biotech Company with Fluctuating Earnings and Revenue Growth. DTIL (Precision BioSciences Inc.) is a biotechnology company that specializes in gene editing and gene therapy. On September 12, 2023, the stock opened at $0.41, slightly lower than the previous day’s closing price …Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human …31 thg 12, 2022 ... Precision BioSciences. 148 views · 11 months ago ...more ... Cramer: This biotech stock could be worth over $100 billion on an FDA approval.Instagram:https://instagram. tax free bonds ratesgilat stockhow to identify real gold at home71 kennedy half dollar value November 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ... tsla technical analysismaking money with forex Precision BioSciences, which has offices at the historic Venable Center in downtown Durham, filed plans on March 1 with the Securities and Exchange Commission for an initial public offering on the Nasdaq stock exchange. The company would trade under the ticker symbol “DTIL,” according to the filing. The company, which has around 130 ... best etfs long term Valuation metrics show that Precision BioSciences, Inc. may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of ...DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023Dec 1, 2023 · The latest price target for Precision BioSciences ( NASDAQ: DTIL) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 3.00 expecting DTIL to ...